TriSalus Life Sciences, Inc. TLSI Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by TriSalus Life Sciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about TriSalus Life Sciences, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TriSalus Life Sciences, Inc.'s accounts receivable?
- TriSalus Life Sciences, Inc. (TLSI) reported accounts receivable of $5.22M in Q1 2026.
- How has TriSalus Life Sciences, Inc.'s accounts receivable changed year-over-year?
- TriSalus Life Sciences, Inc.'s accounts receivable decreased by 4.4% year-over-year, from $5.45M to $5.22M.
- What is the long-term trend for TriSalus Life Sciences, Inc.'s accounts receivable?
- Over 3 years (2022 to 2025), TriSalus Life Sciences, Inc.'s accounts receivable has grown at a 134.6% compound annual growth rate (CAGR), from $1.75M to $22.58M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.